Manufacturing agreement for recombinant Bet v 1 will help take Stallergene’s Oralair into Phase III trials.

Stallergenes and CMC Biopharmaceuticals inked an agreement for development and supply of recombinant Bet v 1 (rBet v 1) purified bulk. The product is the protein that embodies most of the allergenicity of birch pollen, according to Stallergenes.

Scale up the manufacturing of GMP purified recombinant Bet v 1 will be undertaken by CMC Biopharmaceuticals. The company also will produce batches for Phase III trials and commercial supply.

“This agreement will speed our ORALAIR® Bet v 1 project towards late-stage clinical trials and registration while securing the supply of active ingredients for commercial batches,” remarks Albert Saporta, chairman and CEO of Stallergenes.

Stallergenes reports that it has carried out a proof-of-concept trial aimed at demonstrating the ability of Bet v 1 to reduce the symptoms in patients allergic to birch pollen. This double-blind, placebo-controlled study conducted in 150 patients in five countries was highly significant in efficacy and has also shown a good safety profile in the rBet v 1 group versus placebo, similar to the natural extract group, says the firm.

Previous articleBioServe and Seegene to Develop Detection System for Infectious Diseases in India
Next articleVGX Taps DNA Therapeutics Technology from Baylor College of Medicine